DBV Technologies SA
PAR:DBV

Watchlist Manager
DBV Technologies SA Logo
DBV Technologies SA
PAR:DBV
Watchlist
Price: 2.705 EUR 19.16%
Market Cap: 486.4m EUR

DBV Technologies SA
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

DBV Technologies SA
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
DBV Technologies SA
PAR:DBV
Accrued Liabilities
$6.9m
CAGR 3-Years
15%
CAGR 5-Years
-16%
CAGR 10-Years
15%
Valneva SE
PAR:VLA
Accrued Liabilities
€34m
CAGR 3-Years
31%
CAGR 5-Years
27%
CAGR 10-Years
18%
Nanobiotix SA
PAR:NANO
Accrued Liabilities
€6.3m
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
20%
Inventiva SA
PAR:IVA
Accrued Liabilities
€4.5m
CAGR 3-Years
20%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Accrued Liabilities
$7.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
25%
Eurobio Scientific SA
PAR:ALERS
Accrued Liabilities
€4.7m
CAGR 3-Years
-14%
CAGR 5-Years
2%
CAGR 10-Years
7%
No Stocks Found

DBV Technologies SA
Glance View

Market Cap
486.4m EUR
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBV Intrinsic Value
8.028 EUR
Undervaluation 66%
Intrinsic Value
Price

See Also

What is DBV Technologies SA's Accrued Liabilities?
Accrued Liabilities
6.9m USD

Based on the financial report for Jun 30, 2025, DBV Technologies SA's Accrued Liabilities amounts to 6.9m USD.

What is DBV Technologies SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
15%

Over the last year, the Accrued Liabilities growth was 21%. The average annual Accrued Liabilities growth rates for DBV Technologies SA have been 15% over the past three years , -16% over the past five years , and 15% over the past ten years .

Back to Top